JP2023553930A5 - - Google Patents

Info

Publication number
JP2023553930A5
JP2023553930A5 JP2023535327A JP2023535327A JP2023553930A5 JP 2023553930 A5 JP2023553930 A5 JP 2023553930A5 JP 2023535327 A JP2023535327 A JP 2023535327A JP 2023535327 A JP2023535327 A JP 2023535327A JP 2023553930 A5 JP2023553930 A5 JP 2023553930A5
Authority
JP
Japan
Prior art keywords
compound
crystalline form
diffraction pattern
ray powder
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023535327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023553930A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/132028 external-priority patent/WO2022121670A1/zh
Publication of JP2023553930A publication Critical patent/JP2023553930A/ja
Publication of JP2023553930A5 publication Critical patent/JP2023553930A5/ja
Priority to JP2025234453A priority Critical patent/JP2026041905A/ja
Pending legal-status Critical Current

Links

JP2023535327A 2020-12-10 2021-11-22 トレブルチニブの結晶形態、その製造方法、およびその使用 Pending JP2023553930A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025234453A JP2026041905A (ja) 2020-12-10 2025-12-05 トレブルチニブの結晶形態、その製造方法、およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202011455573.5 2020-12-10
CN202011455573 2020-12-10
PCT/CN2021/132028 WO2022121670A1 (zh) 2020-12-10 2021-11-22 Tolebrutinib的晶型及其制备方法和用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025234453A Division JP2026041905A (ja) 2020-12-10 2025-12-05 トレブルチニブの結晶形態、その製造方法、およびその使用

Publications (2)

Publication Number Publication Date
JP2023553930A JP2023553930A (ja) 2023-12-26
JP2023553930A5 true JP2023553930A5 (cg-RX-API-DMAC7.html) 2024-11-29

Family

ID=81974189

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023535327A Pending JP2023553930A (ja) 2020-12-10 2021-11-22 トレブルチニブの結晶形態、その製造方法、およびその使用
JP2025234453A Pending JP2026041905A (ja) 2020-12-10 2025-12-05 トレブルチニブの結晶形態、その製造方法、およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025234453A Pending JP2026041905A (ja) 2020-12-10 2025-12-05 トレブルチニブの結晶形態、その製造方法、およびその使用

Country Status (11)

Country Link
US (2) US12049463B2 (cg-RX-API-DMAC7.html)
EP (1) EP4261212A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023553930A (cg-RX-API-DMAC7.html)
KR (1) KR102872880B1 (cg-RX-API-DMAC7.html)
CN (1) CN118434732A (cg-RX-API-DMAC7.html)
AU (1) AU2021398051B2 (cg-RX-API-DMAC7.html)
CA (1) CA3201936A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023008949A2 (cg-RX-API-DMAC7.html)
IL (1) IL303590A (cg-RX-API-DMAC7.html)
MX (1) MX2023006854A (cg-RX-API-DMAC7.html)
WO (1) WO2022121670A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3168146A1 (en) 2020-01-20 2021-07-29 Genzyme Corporation Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms)
CA3201936A1 (en) 2020-12-10 2022-06-16 Minhua Chen Crystal form of tolebrutinib and preparation method thereof
IL303834A (en) 2020-12-23 2023-08-01 Genzyme Corp 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2H-imidazo[4,5-C]pyridin-2-one derivatives and their salts
CN117295735B (zh) * 2021-04-23 2026-05-12 杭州领业医药科技有限公司 Tolebrutinib晶型、无定型及其制备方法和用途
CN117412749A (zh) * 2021-05-21 2024-01-16 杭州领业医药科技有限公司 Tolebrutinib盐及其晶型、其制备方法、其药物组合物和用途
WO2023280132A1 (zh) * 2021-07-06 2023-01-12 苏州晶云药物科技股份有限公司 氧代二氢咪唑并吡啶类化合物的晶型及其制备方法
CA3241687A1 (en) * 2021-12-21 2023-06-29 Tim Owens Crystalline forms of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one and salts thereof
US20250188076A1 (en) 2022-03-09 2025-06-12 Teva Pharmaceutical International Gmbh Solid state forms of tolebrutinib and of tolebrutinib salts
WO2026050513A1 (en) 2024-08-30 2026-03-05 Principia Biopharma Inc. Tolebrutinib for multiple sclerosis

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3760984A (en) 1971-09-29 1973-09-25 Alza Corp Osmotically powered agent dispensing device with filling means
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
WO2003037890A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Piperidines
US20060045822A1 (en) 2004-09-01 2006-03-02 Board Of Regents, The University Of Texas System Plasma polymerization for encapsulating particles
AU2005284835A1 (en) 2004-09-14 2006-03-23 Novartis Vaccines And Diagnostics Inc. Imidazoquinoline compounds
CA2597587A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
US8846697B2 (en) 2006-05-31 2014-09-30 The Regents Of The University Of California Purine analogs
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
TW200911803A (en) 2007-07-16 2009-03-16 Organon Nv 6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
US8940725B2 (en) 2010-05-31 2015-01-27 Ono Pharmaceutical Co., Ltd. Purinone derivative
AU2012255860C1 (en) 2011-05-17 2015-12-10 Principia Biopharma Inc. Tyrosine kinase inhibitors
MX2013013331A (es) 2011-05-17 2014-10-17 Principia Biopharma Inc Derivados de azaindol como inhibidores de tirosina-cinasas.
US9073947B2 (en) 2011-06-10 2015-07-07 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
BR112014012727B1 (pt) 2011-11-29 2022-10-25 Ono Pharmaceutical Co., Ltd Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
CN104487441B (zh) 2012-06-18 2018-06-01 普林斯匹亚生物制药公司 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶
SMT201900344T1 (it) 2012-09-10 2019-07-11 Principia Biopharma Inc Composti di pirazolopirimidina come inibitori di chinasi
CN102942567B (zh) * 2012-11-09 2017-02-08 诸城市浩天药业有限公司 吡咯并喹啉醌的二钠盐结晶
KR20150084923A (ko) 2012-11-15 2015-07-22 파마시클릭스, 인코포레이티드 키나제 억제제로서의 피롤로피리미딘 화합물
US20140142099A1 (en) 2012-11-20 2014-05-22 Principia Biopharma Inc. Purinone Derivatives as Tyrosine Kinase Inhibitors
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
ME03000B (me) 2012-12-21 2018-10-20 Plexxikon Inc Jedinjenja i metode modulacije kinaze i povezane indikacije
SG11201605417QA (en) 2014-02-03 2016-08-30 Cadila Healthcare Ltd Heterocyclic compounds
AP2016009261A0 (en) * 2014-02-07 2016-06-30 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
CN107001362A (zh) 2014-10-06 2017-08-01 默克专利有限公司 用作btk抑制剂的杂芳基化合物及其用途
JP2016094368A (ja) * 2014-11-14 2016-05-26 大日本住友製薬株式会社 ベンズイミダゾール化合物の新規結晶、及びその製造方法
WO2016086358A1 (en) 2014-12-02 2016-06-09 Merck Sharp & Dohme Corp. Hydroxymethyl piperidine orexin receptor antagonists
EP3912979B1 (en) * 2015-06-03 2026-03-25 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN105753863B (zh) * 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
US10358446B2 (en) 2015-10-14 2019-07-23 Zibo Biopolar Changsheng Pharmaceutical Co., Ltd. Bruton's tyrosine kinase inhibitors
KR102780243B1 (ko) 2015-11-17 2025-03-14 메르크 파텐트 게엠베하 Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물을 사용하여 다발성 경화증을 치료하는 방법
US20210113568A1 (en) 2018-04-27 2021-04-22 Ono Pharmaceutical Co., Ltd. PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT
CA3168146A1 (en) 2020-01-20 2021-07-29 Genzyme Corporation Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms)
CN115867346B (zh) 2020-06-02 2025-03-14 Gb005股份有限公司 激酶抑制剂
WO2022081512A1 (en) 2020-10-12 2022-04-21 Synubi Pharmaceuticals Llc Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors
CA3201936A1 (en) 2020-12-10 2022-06-16 Minhua Chen Crystal form of tolebrutinib and preparation method thereof
IL303834A (en) 2020-12-23 2023-08-01 Genzyme Corp 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2H-imidazo[4,5-C]pyridin-2-one derivatives and their salts
CN117295735B (zh) 2021-04-23 2026-05-12 杭州领业医药科技有限公司 Tolebrutinib晶型、无定型及其制备方法和用途
CN117412749A (zh) 2021-05-21 2024-01-16 杭州领业医药科技有限公司 Tolebrutinib盐及其晶型、其制备方法、其药物组合物和用途
WO2022257845A1 (zh) 2021-06-11 2022-12-15 苏州科睿思制药有限公司 Tolebrutinib的晶型及其制备方法和用途
IL310975A (en) 2021-09-03 2024-04-01 Novartis Ag LOU064 for the treatment of multiple sclerosis
CA3241687A1 (en) 2021-12-21 2023-06-29 Tim Owens Crystalline forms of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one and salts thereof
CN119212708A (zh) 2022-05-13 2024-12-27 普林斯匹亚生物制药公司 用于髓鞘少突胶质细胞糖蛋白抗体疾病(mogad)的治疗性酪氨酸激酶抑制剂
US20260022123A1 (en) 2022-06-22 2026-01-22 Principia Biopharma Inc. Methods of Making Modified BTK Inhibitors
CA3260159A1 (en) 2022-06-30 2024-01-04 Principia Biopharma Inc. Therapeutic Tyrosine Kinase Inhibitors for the Treatment of Multiple Sclerosis and Myasthenia Gravis

Similar Documents

Publication Publication Date Title
JP2023002516A5 (cg-RX-API-DMAC7.html)
JP2018024682A5 (cg-RX-API-DMAC7.html)
JP2023082086A5 (cg-RX-API-DMAC7.html)
JP2023036708A5 (cg-RX-API-DMAC7.html)
JP2012516344A5 (cg-RX-API-DMAC7.html)
JP2020511467A5 (cg-RX-API-DMAC7.html)
RU2598606C3 (ru) Кристаллическая тозилатная соль (8s,9r)-5-фтор-8-(4-фторфенил)-9-(1-метил-1н-1,2,4-триазол-5-ил)-8-9-дигидро-2н-пиридо[4,3,2-de]фталазин-3(7н)-она
JP2021535111A5 (cg-RX-API-DMAC7.html)
JP2016065042A5 (cg-RX-API-DMAC7.html)
HRP20120066T1 (hr) Kalijeva sol inhibitora hiv integraze
JP2011522827A5 (cg-RX-API-DMAC7.html)
JP2012067131A5 (cg-RX-API-DMAC7.html)
JP2014530818A5 (cg-RX-API-DMAC7.html)
RU2007141198A (ru) Кристаллическая форма малеата азенапина
FI3880678T3 (fi) P2x3-muuntaja metyyli-(s)-2-((2-(2,6-difluori-4-(metyylikarbamoyyli)fenyyli)-7-metyyli-imidatso[1,2-a]pyridin-3-yyli)metyyli)morfoliini-4-karboksylaatin kidemuotoja
JP2007532560A5 (cg-RX-API-DMAC7.html)
RU2010133483A (ru) Новые кристаллические формы 4-{4-(2-адамантилкарбамоил)-5-третбутилпиразол-1-ил}бензойной кислоты
JP2015193630A5 (cg-RX-API-DMAC7.html)
JP2015500331A5 (cg-RX-API-DMAC7.html)
JP2019526628A5 (cg-RX-API-DMAC7.html)
RU2015134420A (ru) Кристаллические формы { [1-циано-5-(4-хлорофеноксид)-4-гидроксид-изохинолин-3-карбонил]-амино} -уксусной кислоты
JP2023024108A5 (cg-RX-API-DMAC7.html)
JP2024544538A5 (cg-RX-API-DMAC7.html)
HRP20120700T1 (hr) SOLI SPOJEVA INHIBITORA HIV-a
JP2008513510A5 (cg-RX-API-DMAC7.html)